TauRx announces completion of Phase 3 study enrolment for the first tau-based disease modifying treatment for Alzheimer’s disease
Aberdeen, Scotland and Singapore [January 11, 2021] – TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. TauRx is pleased to be presenting its latest trial results at Biotech Showcase™ 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer’s disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.
Read more here
Recent News
GT Diagnostics announces release of self-administered assessment tool aiding diagnosis of dementia, HiPAL Pro.
Sep 05, 2023
#AAIC23 may have come to a close, but we left Amsterdam with key insights that will drive our work this year.
Jul 21, 2023
TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD)
Jul 16, 2023
As sponsors of the Alzheimer’s Association International Conference® (AAIC®) in Amsterdam 16 – 20 July, together with joint venture company GT Diagnostics, we will be presenting our latest research in neurodegenerative conditions.
Jul 14, 2023